Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwide TEVIMBRA is the cornerstone of BeiGene’s solid tumor portfolio,...
FCS Director of Drug Development Manish Patel, MD Co-Authors BothFORT MYERS, Fla., Sept. 15, 2023 /PRNewswire/ -- Florida Cancer Specialists & Res...
A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of erdafitinib for the treatment of adult patients with locally advanced, unresectable or metastatic urothelial carcinoma harboring susceptible FGFR3 alterations who experienced disease progression during or following at least 1 line of therapy containing a PD-1/PD-L1 inhibitor.
Marwan G. Fakih, MD, expands on long-term findings from the phase 2/3 PROSPECT trial and how these findings may influence the optimal use of nonoperative management strategies in locally advanced rectal cancer.
Evolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.